Jimma University, College of Natural Sciences, Department of Biology, P.O. Box 378, Jimma, Ethiopia.
Parasit Vectors. 2011 Mar 31;4:46. doi: 10.1186/1756-3305-4-46.
Chloroquine is an anti-malarial drug being used to treat Plasmodium vivax malaria cases in Ethiopia. However, emergence of chloroquine resistant strains of the parasite has challenged the current efficacy of the drug. Therefore, the aim of this study was to assess the effectiveness of chloroquine against P. vivax strains in one of the malaria endemic areas of Ethiopia, namely Halaba district, located in South Nations and Nationalities Peoples Region (SNNPR) of South Ethiopia
Among 87 malaria patients enrolled in the study, only 80 of them completed the 28-days follow-up. Seven of them dropped from the study for different reasons. Among those study participants that completed their follow-up, 69 were classified under the category of adequate clinical and parasitological response (ACPR). However, the remaining 11 cases were considered as under treatment failure mainly due to recurrence of parasitemia on day 7 (four patients), day 14 (six patients), and day 21 (one patient). The age of all cases of treatment failures was found to be less than 20 years. The load of parasitemia of patients with treatment failure on day of admission (4709.4/μl) was higher than day of recurrence (372.37/μl). Parasite reduction ratio (PRR) of treatment failure cases was 12.6/μl.
This report revealed the rise in treatment failure (13% [95% CI = 0.074 - 0.217]) as compared to earlier reports from Ethiopia. It signals the spreading of chloroquine resistant P. vivax (CRPv) strains to malaria endemic areas of Ethiopia. It is recommended that all concerned bodies should act aggressively before further expansion of the current drug resistant malaria.
氯喹是一种抗疟药物，目前用于治疗埃塞俄比亚间日疟病例。然而，寄生虫对氯喹的耐药性已经对该药物的现有疗效提出了挑战。因此，本研究旨在评估氯喹对埃塞俄比亚一个疟疾流行地区（即位于埃塞俄比亚南部的南苏丹和民族区域州的哈拉巴区）间日疟原虫株的疗效。
在 87 名纳入研究的疟疾患者中，只有 80 名完成了 28 天的随访。其中 7 人因各种原因退出了研究。在完成随访的研究参与者中，有 69 人被归类为充分的临床和寄生虫学反应（ACPR）。然而，其余 11 例被认为是治疗失败，主要是由于寄生虫血症在第 7 天（4 例）、第 14 天（6 例）和第 21 天（1 例）复发。所有治疗失败病例的年龄均小于 20 岁。治疗失败患者入院时（4709.4/μl）的寄生虫载量高于复发时（372.37/μl）。治疗失败病例的寄生虫减少率（PRR）为 12.6/μl。
与之前来自埃塞俄比亚的报告相比，本报告显示治疗失败（13%[95%CI=0.074-0.217]）有所增加。这表明氯喹耐药间日疟原虫（CRPv）株已传播到埃塞俄比亚的疟疾流行地区。建议所有有关机构在当前抗疟药物耐药性进一步扩大之前，应采取积极行动。
